Phase 2 proof-of-concept study ERY001 in the patients with triple negative breast cancer
Phase of Trial: Phase II
Latest Information Update: 15 Nov 2018
At a glance
- Drugs ERY-ASP (Primary)
- Indications Breast cancer
- Focus Proof of concept; Therapeutic Use
- 15 Nov 2018 According to an ERYtech Pharma media release, the company has a red blood cell supply and research partnership with New York Blood Center (NYBC) for this and other trial (see profile 285388). This trial is expected begin enrollment in the United States early in 2019.
- 10 Sep 2018 According to an ERYtech Pharma media release, first patient is expected to enroll in Q4 2018.
- 15 Feb 2018 New trial record